Search Results
Sep 15, 2025, 08:00 ET Matica Bio Secures Commercial Manufacturing Deal with U.S. Biotech Company
Matica Bio), a leading contract development and manufacturing organization (CDMO) specializing in viral vector manufacturing for cell and gene therapies, today announced a strategic commercial manufacturing agreement with a clinical-stage biotech company based in the
More news about: Matica Biotechnology, Inc.
Sep 15, 2025, 07:31 ET You've never seen corn like this before
single-cell RNA sequencing, allows researchers to see how genes are expressed in thousands of cells at once. "The great thing is that you have this atlas of gene expression," Jackson says. "When we publish that, the whole community can use it. Other people interested in maize or Arabidopsis stem cells don't have
More news about: Cold Spring Harbor Laboratory
Sep 15, 2025, 07:30 ET Abzena Enhances AbZelectPRO™ Cell Line Offering with New GS Knockout Platforms
UNic® vector technology. ProteoNic collaborates with partners across the biopharmaceutical industry to bring innovative biologics as well as cell and gene therapies to market faster and more efficiently. For more information, visit proteonic.nl.
More news about: Abzena
Sep 15, 2025, 07:00 ET Deerfield Management and the Deerfield Foundation Announce Third Annual AML Summit and Recipient of American Society of Hematology (ASH) Peter Steelman Scholar Award
enhancing targeted immunotherapies and improving outcomes for patients with blood cancers. Dr. Casirati's research has contributed to the development of gene-editing approaches aimed at making bone marrow transplants and CAR-T cell therapies safer and more effective. "Congratulations to Gabriele Casirati,
More news about: Deerfield Management Company, L.P.
Sep 15, 2025, 06:00 ET Gyala Therapeutics unveils first-in-class CAR-T therapy targeting CD84 showing strong preclinical efficacy in hard-to-treat leukemias
eradicating disease and prolonging survival.Robust expansion from both healthy donor and patient T cells, with a favorable memory phenotype and no gene editing required to avoid fratricide.The study confirms that CD84 is consistently overexpressed in AML and T-ALL, including high-risk subtypes
More news about: Gyala Therapeutics
Sep 15, 2025, 06:00 ET Gyala Therapeutics unveils first-in-class CAR-T therapy targeting CD84 showing strong preclinical efficacy in hard-to-treat leukemias
eradicating disease and prolonging survival.Robust expansion from both healthy donor and patient T cells, with a favorable memory phenotype and no gene editing required to avoid fratricide.The study confirms that CD84 is consistently overexpressed in AML and T-ALL, including high-risk subtypes
More news about: Gyala Therapeutics
Sep 12, 2025, 10:01 ET Ligase Enzymes Market worth US$0.36 billion by 2030 with 6.8% CAGR | MarketsandMarkets™
applications continue to dominate due to their essential role in academic research, functional genomics, and biopharmaceutical development. The growth of gene therapy and the expansion of recombinant protein production pipelines further reinforce the demand for ligase enzymes in cloning. Moreover, technological
More news about: MarketsandMarkets
Sep 12, 2025, 04:43 ET Kanazawa University research: Thermal trigger
other biomolecules, additional thermogenetic tools can be developed to modulate various cellular functions, such as enzyme activity, protein–protein interactions, and gene expression." Figure 1.
More news about: Kanazawa University
Sep 12, 2025, 01:51 ET IASO Bio to Present Promising Findings on Equecabtagene Autoleucel for Multiple Sclerosis at both ANA and ECTRIMS 2025
(Eque-cel) Equecabtagene Autoleucel (Eque-cel) is an innovative fully human anti-BCMA CAR-T cell therapy which uses lentivirus as a gene vector to transfect autologous T cells. The CAR contains a fully human scFv, CD8a hinge and transmembrane, and 4-1BB co-stimulatory and CD3ζactivation
More news about: IASO Bio
Sep 12, 2025, 01:14 ET Performance Brokerage Services Advises on the Sale of Saskatchewan's #1 RV Dealer, Minard's Leisure World in Weyburn and Watrous to Traveland RV
Watrous, Saskatchewan from Susan and Gene Minard to Traveland RV. Minard's Leisure World, founded in 2004 by Susan and Gene Minard, is the #1 volume RV dealer in Saskatchewan.
More news about: Performance Brokerage Services, Inc.
Sep 11, 2025, 17:31 ET Dyslipidemia Market is Anticipated to Accelerate in the Coming 10 Years Due to the Development of New Classes of Drugs, Such as CETP Inhibitors and Gene-based Therapies | DelveInsight
Dyslipidemia Drug Classes Development of new classes of drugs, such as CETP inhibitors (NewAmsterdam Pharma's Obicetrapib) and gene-based therapies, holds promise for better management of dyslipidemia. Launch of Emerging Dyslipidemia Drugs The dyslipidemia
More news about: DelveInsight Business Research, LLP
Sep 11, 2025, 12:02 ET Precision Medicine Market to Reach USD 103.73 Billion by 2035, with CAGR 11.3% Driven by Genomics, AI Integration, and Targeted Therapies - Vantage Market Research
especially in oncology. The Therapeutics segment is expanding rapidly, driven by monoclonal antibodies, gene therapy, and cell therapy. Among these, monoclonal antibodies hold the largest share, while gene and cell therapies are witnessing the fastest growth with approvals for rare diseases and advanced cancers.
More news about: Vantage Market Research
Sep 11, 2025, 09:41 ET Gene Solutions Secures Patent(1) for Breakthrough Mitochondrial Therapy Platform Targeting Neurological Diseases
groundbreaking technology, collaborative opportunities, or the company's therapeutic programs, please visit the Gene Solutions website or contact the company directly. About Gene SolutionsGene Solutions is a biotechnology company specializing in therapeutic research for CNS diseases, with a
More news about: Gene Solutions
Sep 11, 2025, 08:46 ET Korea University Study Reveals Hidden Complexity in Recurrent Brain Tumors
Single-cell insights uncover the gene driving recurrence and treatment resistance in meningiomas SEOUL, South Korea, Sept. 11, 2025 /PRNewswire/
More news about: Korea University College of Medicine
Sep 11, 2025, 08:17 ET Nicholas Richardson, DO, MPH, Departs FDA and Joins Precision for Medicine as VP, Clinical Development
role, Dr. Richardson will be responsible for partnering with life science companies on the clinical development of their drugs, biologics, and cell and gene therapies.
More news about: Precision Medicine Group
Sep 11, 2025, 08:05 ET YolTech Therapeutics Raises $45 Million in Series B Financing Led by AstraZeneca-CICC
therapies. We are committed to turning cutting-edge gene-editing science into real-world treatments for patients worldwide." About YolTech TherapeuticsFounded in 2021, YolTech Therapeutics is advancing next-generation in vivo gene-editing therapies designed for one-time treatment.
More news about: YolTech Therapeutics
Sep 11, 2025, 08:00 ET PhenoVista Biosciences and Carolina Molecular Announce Partnership to Extend Multi-omic Data Access to Clients
functional and phenotypic, cellular data with orthogonal, molecular readouts, including robust immunoassay technologies for detecting key protein markers and gene expression analysis using targeted qPCR assays or broader transcriptomic profiling via RNA sequencing. By combining Carolina Molecular's molecular testing
More news about: Carolina Molecular
Sep 11, 2025, 04:27 ET Inpharmus Becomes a Leader in Rare Diseases and Oncology in the MERAT
flexible and proactive structure, while also investing in future models of care. On the future of medicine, Ince noted: "In the near future, gene and personalized therapies will take center stage, and at Inpharmus, we aim to be at the forefront of that transformation. One clear example is the
More news about: Inpharmus
Sep 11, 2025, 04:07 ET Inpharmus Becomes a Leader in Rare Diseases and Oncology in the MERAT
while also investing in future models of care. On the future of medicine, Ince noted: "In the near future, gene and personalized therapies will take center stage, and at Inpharmus, we aim to be at the forefront of that transformation. One clear example is the
More news about: Inpharmus
Sep 11, 2025, 02:27 ET Lundbeck showcases new clinical migraine data, including long-term preventive effectiveness of Vyepti® (eptinezumab) in patients severely impacted by migraine
questionnaire domain scores. About Vyepti® (eptinezumab) Eptinezumab is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) which was intentionally designed for IV administration. The efficacy and safety of eptinezumab was evaluated in two phase III
More news about: H. Lundbeck A/S
Sep 11, 2025, 02:23 ET Lundbeck showcases new clinical migraine data, including long-term preventive effectiveness of Vyepti® (eptinezumab) in patients severely impacted by migraine
questionnaire domain scores. About Vyepti® (eptinezumab) Eptinezumab is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) which was intentionally designed for IV administration. The efficacy and safety of eptinezumab was evaluated in two phase III
More news about: H. Lundbeck A/S
Sep 11, 2025, 01:03 ET Ecovyst Announces Agreement to Sell its Advanced Materials & Catalyst Segment to Technip Energies
information, future developments or otherwise, except as may be required by applicable law. For more information:Gene Shiels – Director of Investor Relations(484) 617 [email protected]
More news about: Ecovyst Inc.
Sep 10, 2025, 23:30 ET HaemaLogiX wins "Most Promising CAR-T Pipeline in APAC" at the Asia Pacific CGT¹ Excellence Awards 2025
unmet medical need for safer and more efficacious treatment options. ENDS References: 1. CGT = Cell and Gene Therapy Photo -
More news about: HaemaLogiX
Sep 10, 2025, 23:16 ET HaemaLogiX wins "Most Promising CAR-T Pipeline in APAC" at the Asia Pacific CGT¹ Excellence Awards 2025
unmet medical need for safer and more efficacious treatment options. ENDS References: 1. CGT = Cell and Gene Therapy
More news about: HaemaLogiX
Sep 10, 2025, 09:48 ET Israel Cancer Research Fund Surpasses $100 Million in Total Funding as New Grants Are Awarded
scientists for their innovative research, and past and present grantees have played key roles related to advancements in DNA methylation, BRCA, the RAD51 gene, novel bone marrow transplant technique, and much more. As Israel and its people continues to face
More news about: Israel Cancer Research Fund